Skip to main content
Clinical Trials/NCT04733885
NCT04733885
Completed
N/A

Evaluation of the Effects of Electrical Stimulation in Women With Pelvic Organ

KTO Karatay University1 site in 1 country26 target enrollmentFebruary 15, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pelvic Organ Prolapse
Sponsor
KTO Karatay University
Enrollment
26
Locations
1
Primary Endpoint
The prolapse stage will be measured with Simplified POP-Q
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to search the effects of electrical stimulation on clinical symptoms such as pelvic floor muscle strength, stage of POP, symptoms of pelvic floor, quality of life and sexual function in women with pelvic organ prolapse (POP)

Detailed Description

This study is planned as a prospective, sham radomized controlled study. Individuals who volunteered to participate in the study, complying with the inclusion criteria and signed the consent paper will be randomly allocated into ES and Sham ES groups. The study includes women aged 18-65 diagnosed with staged 1-2 POP by the physician.All patients were evaluated by the same doctor who performed the POP-Q measurement, who was blinded to the baseline results. The treatment of patients will be given by the same therapist. Measurements will be made 3 times at baseline (before treatment), interim period (4th week) and after treatment.

Registry
clinicaltrials.gov
Start Date
February 15, 2021
End Date
February 1, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
KTO Karatay University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Being in the age range of 18-65 ,
  • Having stage1-2 symptomatic prolapse according to the POP-Q system,
  • Being a volunteer and literate

Exclusion Criteria

  • Being pregnant,
  • being stage 3-4 prolapse, Those whose evaluation parameters are missing and who do not regularly participate,
  • Inadequate understanding and cooperation in treatment and evaluation parameters,
  • Have malignant disease, urinary infection,
  • accompanying neurological disease, diabetes mellitus and cardiopathy with complications,
  • have electronic and metal implant, loss of sensation, sacral peripheral nerve lesion
  • Patients with at least one of the kidney failure requiring hemodialysis

Outcomes

Primary Outcomes

The prolapse stage will be measured with Simplified POP-Q

Time Frame: Change from baseline prolapse stage at 4 weeks and 8 weeks

The measurements are taken when the Valsalva maneuver is performed while the patient is in the dorsal lithotomy position. According to the reference point of the hymen, It is measured at a total of 4 points: cervix, posterior fornix, anterior and posterior vaginal wall. The stage of prolapse is graded. Stage 0: There is no prolapse. Stage 1: The most distal part of the prolapse is more than 1 cm above the prolapse. Stage 2: The most distal part of the prolapse, between 1 cm above and 1 cm below the prolapse Stage 3: The most distal part of the prolapse protrudes more than 1 cm below the prolapse. Stage 4: Complete eversion of the lower genital tract

Secondary Outcomes

  • Pelvic floor muscle strength will be measured measured with PFX Perineometer device(Cardio Design Pty Ltd, Australia)(Change from baseline Pelvic floor muscle strength at 4 weeks and 8 weeks)
  • The pelvic organ prolapse symptoms will be assessed by Pelvic Organ Prolapse Symptom Score(POP-SS).(Change from baseline the pelvic organ prolapse symptoms at 4 weeks and 8 weeks)
  • Patients' quality of life will be assessed using the Prolapse Quality of Life Scale (P-QOL).(Change from baseline quality of life at 4 weeks and 8 weeks)
  • The pelvic organ prolapse symptoms severity will be assessed by the Pelvic Floor Distress Inventory (PFDI-20) .(Change from baseline the pelvic organ prolapse symptoms severity at 4 weeks and 8 weeks)
  • Patients' sexual function will be assessed by the Pelvic Organ Prolapse/Incontinence Sexual Function Questionnaire-12 (PISQ-12)(Change from baseline sexual function at 4 weeks and 8 weeks)

Study Sites (1)

Loading locations...

Similar Trials